Roivant Sciences Ltd. (ROIV)

Roivant Sciences Ltd. is trading at $33.62, up 0.81% on the session. The 50 day average sits at $36.70 and the 200 day at $30.56, which puts the stock in a uptrend. RSI is at 39.9, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $33.43 with resistance near $35.70, so that band frames the current range. Average daily movement is roughly $1.30, or about 3.9% of the share price, which is what any stop placement has to allow for. The overall health score of 56 out of 100 combines a trend score of 73, momentum of 20 and a risk score of 81.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.